A phase II trial of PS-341 in combination with paclitaxel and carboplatin for the treatment of metastatic melanoma

Trial Profile

A phase II trial of PS-341 in combination with paclitaxel and carboplatin for the treatment of metastatic melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2013

At a glance

  • Drugs Bortezomib (Primary) ; Carboplatin; Paclitaxel
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Jul 2012 New source identified and integrated (Mayo Clinic).
    • 19 Jul 2012 Status changed from completed to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top